INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Systematic review / meta-analysis / 2024

Semaglutide and tirzepatide led to substantial reductions in body weight and waist circumference in people with obesity without diabetes.

A systematic review and meta-analysis of seven randomized controlled trials (n = 5,140) evaluated once-weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10 or 15 mg in individuals with obesity without diabetes. Across the therapies, the placebo-subtracted difference in body weight was -15.0% (-12.9% for semaglutide and -19.2% for tirzepatide), and the reduction in waist circumference was -11.4 cm (-9.7 cm for semaglutide and -14.6 cm for tirzepatide). Adverse events were mainly mild-to-moderate, mostly gastrointestinal, and more common during dose titration before leveling off.

Study type
Systematic review and meta-analysis of randomized controlled trials
Who was studied
5,140 people with obesity without diabetes across 7 randomized controlled trials
What was measured
Placebo-subtracted differences in body weight, waist circumference, and safety

THE PAPER

Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety.

Müllertz ALO, Sandsdal RM, Jensen SBK, Torekov SS. Obes Rev, 2024.

PubMed 38463003 ↗DOI 10.1111/obr.13717 ↗

Gut & microbiomeWeight & appetite

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.